Strategic Expansion of Minority Investments
In an exciting move to bolster its market position, BrainsWay Ltd. (NASDAQ & TASE: BWAY) has announced two new minority-stake investments in leading U.S. mental health providers. This brings the total number of strategic investments made by the company in 2025 to four, a clear indication of its commitment to enhancing patient care and access to advanced mental health treatments.
Investments with Impact
The latest agreements include a significant equity financing arrangement with Tangient ATX Inc., which operates the innovative Heading Health mental health clinic network across multiple Texas locations. BrainsWay will initially invest $1.5 million in Heading Health, with the potential for an additional $2.5 million based on performance milestones. This partnership is poised to facilitate deeper access and awareness of groundbreaking mental health therapies, particularly the company's proprietary Deep TMS (Transcranial Magnetic Stimulation) technology.
According to Hadar Levy, the CEO of BrainsWay, these investments are part of a broader strategy aimed at driving sustainable shareholder value while focusing on the scientific advancements that underpin their treatment technologies. The partnership with Heading Health is expected to accelerate patient access to innovative therapies designed to improve mental health outcomes.
Insights from Leadership
Simon Tankel, CEO of Tangient, emphasized the unique opportunity of collaborating with BrainsWay, referring to them as the preeminent innovator in neuromodulation technology. The agreement indicates a shared commitment to enhancing patient lives through effective treatment options.
Aside from Heading Health, BrainsWay has secured another smaller investment with an east-coast based mental health provider. These strategic minority investments underscore the company's vision to empower its commercial partners while reinforcing its core focus on research and technology development in mental health.
About BrainsWay
Founded in 2003, BrainsWay is at the forefront of noninvasive neurostimulation therapies for mental health challenges. Its Deep TMS™ platform is groundbreaking, holding three FDA-cleared indications supported by robust clinical evidence. The company addresses conditions such as major depressive disorder, obsessive-compulsive disorder, and smoking addiction, continuously advancing the field of neurotherapy.
BrainsWay is committed to expanding global awareness and accessibility of its innovations. Ongoing clinical trials are exploring the efficacy of Deep TMS in various psychiatric and neurological disorders, affirming the company's dedication to transforming lives through superior scientific advancements.
The Future of Mental Healthcare
The mental health crisis continues to grow worldwide, making BrainsWay's efforts particularly timely and critical. By forging strategic partnerships with prominent mental health providers, the company aims to enhance treatment delivery methods, and improve patient outcomes on a larger scale.
As the field of mental healthcare evolves, BrainsWay’s role as an innovator in neuromodulation is pivotal. Their investments serve to strengthen not only their market position but also the entire mental health sector, focusing on providing effective, evidence-based treatments to those in need.
A Commitment to Innovation
BrainsWay’s current and future clinical trials delve into uncharted territories in the mental health realm, broadening the potential applications of Deep TMS technology. As they continue to accumulate clinical evidence and refine their approaches, the advancements could lead to more effective solutions for various mental health conditions.
Frequently Asked Questions
What is BrainsWay's primary focus?
BrainsWay focuses on developing advanced noninvasive neurostimulation treatments for mental health disorders.
What is Deep TMS technology?
Deep TMS (Transcranial Magnetic Stimulation) is a proprietary platform designed to treat conditions like depression and anxiety, among others.
How much is BrainsWay investing in Heading Health?
BrainsWay is initially investing $1.5 million in Heading Health with potential additional investments based on performance.
How many minority-stake investments has BrainsWay made in 2025?
As of now, BrainsWay has completed four minority-stake investments in 2025.
Why are these investments significant?
These investments are significant as they aim to enhance patient access to innovative mental health treatments and drive long-term shareholder value.
